Researchers in Pennsylvania conducted a randomized controlled trial to understand the effect of patient outreach on lung cancer screening rates.
New findings from a randomized controlled trial revealed outreach contacts significantly increased lung cancer screening (LCS) among primary care patients across 4 practices in Pennsylvania. Results were published in Preventive Medicine.
Although previous data has indicated periodic low dose computed tomography (LDCT) screening can significantly reduce lung cancer mortality, LCS rates are low in the United states with one assessment concluding the current rate among eligible patients is 4.5%, compared with a 7.5% target goal, researchers explained.
CMS does cover the service for individuals aged 55 to 77 and “have at least a 30 pack-year smoking history and currently smoke, or have a history of heavy smoking but have quit smoking within the past 15 years,” as recommended by the United State Preventive Service Task Force (USPSTF).
But the agency also requires shared decision making (SDM) about LCS prior to completion, an infrequent occurrence in clinical practice, according to authors.
In an effort to determine the effects of patient outreach and SDM strategies on LCS uptake, investigators conducted a randomized controlled trial of patients receiving care at Jefferson Health in Pennsylvania.
Of the 4 practices included in the study, 2 were Family and Community Medicine practices and 2 were Internal Medicine practices. In addition, “2 practices (1 Family and Community Medicine and 1 Internal Medicine) served primarily English-speaking white and African American patients. One Family and Community Medicine practice served primarily Chinese patients, and the remaining Internal Medicine practice served mostly Korean patients,” authors wrote.
Eligible participants were identified via electronic medical record (EMR) data, and patients were randomized to an outreach contact plus decision counseling (OC-DC) group, an outreach contact alone (OC) group, or usual care control group (UC).
A total of 2347 patients were included in the final analyses with 302 in the OC-DC group, 297 in the OC group and 1748 in the UC group. A slim majority of patients (52%) were female while 31% were African American and 7% were Asian.
Analyses revealed:
Overall, screening completion was significantly higher among those who received some form of outreach contact compared with patients receiving usual care. This could be due to an increase in LCS referral and scheduling for the service. While SDM incorporation appeared to have an additive effect, more research is needed to assess this addition to care.
“Even when extended follow-up (up to 9 months) was considered, during which many of the usual care group participants were likely to have had a routine care visit with their provider, their LCS screening rate did not catch up with that of the intervention groups,” authors noted.
Due to limited data in EMRs, researchers were unable to ascertain intervention impact among those with verified LCS eligibility, marking a limitation to the study. Generalizability of findings may also be limited and may not apply to all primary care practices.
Reference:
DiCarlo M, Myers P, Daskalakis C, et al. Outreach to primary care patients in lung cancer screening: a randomized controlled trial. Prev Med. Published online April 22, 2022. doi:10.1016/j.ypmed.2022.107069
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More